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Marginal structural models for the estimation of
the risk of Diabetes Mellitus in the presence of
elevated depressive symptoms and antidepressant
medication use in the Women’s Health Initiative
observational and clinical trial cohorts
Christine Frisard1*, Xiangdong Gu2, Brian Whitcomb2, Yunsheng Ma1, Penelope Pekow2, Martha Zorn2,
Deidre Sepavich1 and Raji Balasubramanian2
Abstract
Background: We evaluate the combined effect of the presence of elevated depressive symptoms and antidepressant
medication use with respect to risk of type 2 diabetes among approximately 120,000 women enrolled in the Women’s
Health Initiative (WHI), and compare several different statistical models appropriate for causal inference in non-
randomized settings.
Methods: Data were analyzed for 52,326 women in the Women’s Health Initiative Clinical Trials (CT) Cohort and 68,169
women in the Observational Study (OS) Cohort after exclusions. We included follow-up to 2005, resulting in a median
duration of 7.6 years of follow up after enrollment. Results from three multivariable Cox models were compared to
those from marginal structural models that included time varying measures of antidepressant medication use,
presence of elevated depressive symptoms and BMI, while adjusting for potential confounders including age, ethnicity,
education, minutes of recreational physical activity per week, total energy intake, hormone therapy use, family history
of diabetes and smoking status.
Results: Our results are consistent with previous studies examining the relationship of antidepressant medication use
and risk of type 2 diabetes. All models showed a significant increase in diabetes risk for those taking antidepressants.
The Cox Proportional Hazards models using baseline covariates showed the lowest increase in risk , with hazard ratios
of 1.19 (95 % CI 1.06 – 1.35) and 1.14 (95 % CI 1.01 – 1.30) in the OS and CT, respectively. Hazard ratios from marginal
structural models comparing antidepressant users to non-users were 1.35 (95 % CI 1.21 – 1.51) and 1.27 (95 % CI 1.13 –
1.43) in the WHI OS and CT, respectively – however, differences among estimates from traditional Cox models and
marginal structural models were not statistically significant in both cohorts. One explanation suggests that time-
dependent confounding was not a substantial factor in these data, however other explanations exist. Unadjusted Cox
Proportional Hazards models showed that women with elevated depressive symptoms had a significant increase in
diabetes risk that remained after adjustment for confounders. However, this association missed the threshold for
statistical significance in propensity score adjusted and marginal structural models.
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* Correspondence: Christine.Frisard@umassmed.edu
1Division of Preventive and Behavioral Medicine, Department of Medicine,
University of Massachusetts Medical School, 55 Lake Avenue North,
Worcester, MA 01655, USA
Full list of author information is available at the end of the article
© 2015 Frisard et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Frisard et al. BMC Endocrine Disorders  (2015) 15:56 
DOI 10.1186/s12902-015-0049-7
(Continued from previous page)
Conclusions: Results from the multiple approaches provide further evidence of an increase in risk of type 2 diabetes
for those on antidepressants.
Keywords: Antidepressant medication, Depression, Type 2 diabetes, Marginal structural models, Propensity score
Background
Diabetes is a chronic illness with serious health conse-
quences, such as adult blindness, non-traumatic limb
amputation, renal failure and neuropathy. Previous lit-
erature has noted considerable diabetes and depression
among postmenopausal women, with a prevalence rate
that is approximately 12 % for each [1, 2]. Recent lit-
erature also suggests an increased risk of diabetes
among those who are depressed and on antidepres-
sant medications [3 –6 ]. It is increasingly important
to further investigate whether depression or anti-
depressant medication is influencing this association
given that approximately 11 % of American women
take antidepressant medication, and use is rising [7].
While the rates of use for depression treatment has
remained the same, off-label use of antidepressants
has increased significantly [8]. Examples of off-label
use include treatment for certain types of pain, fibro-
myalgia, insomnia, and general unhappiness. In this
analysis, we compare four statistical approaches to
evaluate the combined effect of the presence of ele-
vated depressive symptoms and antidepressant medica-
tion use on incident type 2 diabetes using data on
approximately 120,000 women in the Women’s Health
Initiative (WHI).
The WHI is a longitudinal study including repeated
measurements for presence of elevated depressive symp-
toms, antidepressant use and self-reported diagnosis of
type 2 diabetes. A previously reported analysis in the
WHI [9] found that elevated depressive symptoms and
antidepressant medication use resulted in increased type
2 diabetes risk. This analysis was based on Cox models
that are subject to bias in the presence of time-
dependent confounding [10–12]. A probable mechanism
that gives rise to time-dependent confounding in this
context is shown in Fig. 2 (Appendix) - participants with
increased BMI could be more likely to be depressed
and/or on antidepressants in the future [13]. Moreover,
BMI and depression/antidepressant medication use can
also significantly influence future diabetes risk. Thus,
an analysis based on Cox models as in the previous
literature [9] to evaluate the causal relationship be-
tween presence of elevated depressive symptoms/anti-
depressant use (exposure) and diabetes risk (outcome)
could result in biased estimates by misattributing the
effects of time-dependent confounders to the expo-
sures of interest.
In the presence of time-dependent confounding, all
Cox models including those that incorporate time-
varying covariates are subject to bias [10–12]. Marginal
structural models (MSMs) overcome limitations of Cox
models - MSMs use inverse probability of treatment/
exposure weighting and, given assumptions, can yield
consistent and unbiased causal estimates of the effect
of exposure [10–12]. Other methods in this setting in-
clude propensity score adjusted models in which the
probability of treatment assignment conditional on
baseline covariates (or propensity score) is adjusted for
as an additional covariate.
The objective of this work was to estimate the com-
bined effect of antidepressant medication use/presence
of elevated depressive symptoms on type 2 diabetes in
the WHI, and to compare results obtained from MSMs
and propensity score adjusted Cox models to more
traditional approaches such Cox models [9, 14, 15].
The results presented in this paper go beyond a previ-
ously reported analysis of this hypothesis in the WHI
[9] by comparing results from four different statistical
approaches including MSMs that are recommended for
causal inference in observational studies.
Methods
Women’s health initiative (WHI)
The WHI enrolled 68,132 participants into clinical trials
(WHI-CT) and 93,676 participants into an observational
study (WHI-OS) between 1993 and 1998 [16–19]. Eligibil-
ity criteria included: postmenopausal women aged 50 to
79 years, reliable/mentally competent, and expected sur-
vival and local residency for at least three years. Medica-
tion use, presence of elevated depressive symptoms, and
diabetes status were collected from participants over an
average of 7.6 years of follow-up. We analyzed data with
follow-up to 2005.
Study variables
Incident diabetes
Diabetes status was assessed by self-report at baseline and
at each annual follow-up visit, which has been found to be
a reliable indicator of diagnosed diabetes [20]. Time to
diabetes was calculated as the interval between study en-
rollment and development of diabetes as evidenced by an
annual medical history update, or censorship (death or
end of study participation).
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Antidepressant medication use
WHI-CT participants were instructed to bring all current
prescription and nonprescription medications in ori-
ginal containers to clinic visits at baseline and years
1, 3, 6, and 9. WHI-OS medication data were col-
lected at baseline and year 3. The Master Drug Data
Base (MDDB: Medi-Span, Indianapolis, IN) was used to
categorize the medications. Based on the MDDB classifi-
cation, a binary indicator for antidepressant medication
use was created. Antidepressants include the following
major groups: 1) Selective serotonin reuptake inhibi-
tors; 2) Monoamine oxidase inhibitors; 3) Tricyclic
antidepressants; 4) Tetracyclics; 5) Serotonin/norepin-
ephrine reuptake inhibitors (SNRIs); 6) Aminoketones;
7) Triazolopyridines; and 8) Dibenzoxazepine. A di-
chotomous indicator of antidepressant medication use
was then created for each measurement period [9].
Due to sample size limitations, we did not perform
analyses by class of medication.
Elevated depressive symptoms
Elevated depressive symptoms were measured using the
6-item Center for Epidemiological Studies Depression
Scale (CES-D) [21]. A participant was determined to
have elevated depressive symptoms if their score was 5
or higher on the CES-D. Presence of elevated depressive
symptoms was available at baseline and year 3 in the
WHI-OS and at baseline, year 1, and close out in the
WHI-CT. Only 6 % of participants were assessed at
years 3, 6, and 9. Due to high levels of missing values at
year 1 and later, analysis in the CT cohort adjusted only
for baseline presence of elevated depressive symptoms.
BMI
BMI was available at baseline and year 3 in the WHI-OS
and at baseline, years 1, 3, 6 and 9 in the WHI-CT.
Other covariates
Other variables available at baseline for inclusion in multi-
variable models include: age, race/ethnicity (American
Indian/Alaskan Native; Asian or Pacific Islander; Black/
African American; Hispanic/Latino; White; Other), educa-
tion (<=high school; high school or GED; > = high school,
but less than 4 years of college; 4 or more years of college),
minutes of recreational physical activity per week, total
energy intake, hormone therapy use (never, former,
current), family history of diabetes (no, yes, don’t know)
and smoking status (never smoked, past smoker, current
smoker).
Statistical analysis
Analysis datasets
WHI OS: included 68,169 women after exclusions for
self-reported diagnosis of diabetes at baseline or missing
data on one or more of the following: baseline diabetes
status, race/ethnicity, presence of elevated depressive
symptoms, antidepressant medication use, BMI or
women for whom the Year 3 visit occurred more than
3.5 years post enrollment (Fig. 1). 3624 (5.3 %) women
reported diagnosis of type 2 diabetes during follow-up.
Antidepressant use, BMI, presence of elevated depressive
symptoms was available at baseline and year 3 and in-
cluded in analyses.
WHI CT: included 52,326 women after the following
exclusions - women with a self-reported diagnosis of
diabetes at baseline or missing data on one or more of
the following: diabetes status at baseline, race/ethni-
city, baseline presence of elevated depressive symp-
toms, antidepressant medication use, BMI (Fig. 1).
4171 (8.0 %) women reported diagnosis of type 2 dia-
betes during follow-up. Antidepressant use and BMI
were recorded at baseline, year 1 and year 3. Models
adjusted for presence of elevated depressive symptoms
at baseline because presence of elevated depressive
symptoms was only measured on a small percentage
(6.26 %) of women after year 1.
Statistical models
We compared results from four approaches for estimating
the association between the presence of elevated depres-
sive symptoms/antidepressant medication use with inci-
dent type 2 diabetes, in the WHI-OS and WHI-CT
datasets separately. Results reported by Ma and colleagues
[9] were based on multivariable Cox models as in
Approach 1 and Approach 2 described below. The results
from these models were compared to propensity score ad-
justed models (Approach 3) and MSMs (Approach 4)
[22–25]. The interaction of elevated depressive symptoms
and antidepressant medication use was investigated in all
models, but all interactions were insignificant (p > 0.26 in
WHI-OS, p > 0.06 in WHI-CT).
Approach 1 is a Cox proportional hazards (PH) model
including the following covariates at baseline: elevated de-
pressive symptoms, antidepressant use, BMI, age, ethni-
city, education, minutes of recreational physical activity
per week, total energy intake, hormone therapy use, family
history of diabetes and smoking status.
Approach 2 is a Cox model with time-varying values
of elevated depressive symptoms (WHI-OS only), anti-
depressant medication use and BMI, and baseline
values of age, ethnicity, education, minutes of recre-
ational physical activity per week, total energy intake,
hormone therapy use, family history of diabetes and
smoking status.
Approach 3 is similar to Approach 2, with additional
adjustment for propensity for taking antidepressants at
baseline. The propensity score was calculated to predict
antidepressant use at baseline (outcome) from a logistic
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model. Predictors included in the model were baseline
measures of BMI, age, ethnicity, education, minutes of
recreational physical activity per week, total energy in-
take, hormone therapy use, family history of diabetes
and smoking status.
Approach 4 is a MSM for a time to event outcome
[10]. Two separate logistic regression models were fit to
calculate the probability of being on antidepressants and
the probability of censoring (not observing the outcome
by that point in time). The models incorporated time-
varying data on the presence of elevated depressive
symptoms and BMI while adjusting for baseline values
of age, ethnicity, education, minutes of recreational
physical activity per week, total energy intake, hormone
therapy use, family history of diabetes and smoking sta-
tus. These models were used to determine the stabilized
Inverse Probability of Treatment (IPTW) weights. In the
WHI-CT analysis, models were also adjusted for clinical
Fig. 1 Flow chart describing analytic cohort included for the investigation (N = 120,495)
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site. To relax the linearity assumption, we added a quad-
ratic function of time to the model. Model details and
associated SAS code are included in the Appendix.
Results
Table 1 presents baseline characteristics of our study
population, by antidepressant medication use. Baseline
characteristics by presence of elevated depressive symp-
toms are shown in Table 4 (Appendix). In both cohorts,
the mean age was approximately 63 years old (63.6 (OS);
62.8 (CT)). Women were primarily White (86.5 % (OS);
84.4 % (CT)) and most had greater than high school
education (80 % (OS); 76.4 % (CT)). Approximately 30 %
of women on antidepressants had elevated depressive
symptoms (28.2 % (OS); 29.8 % (CT)). A greater percent-
age of antidepressant medication users than non-users
reported current use of hormone replacement therapy
(64.9 % vs. 49.7 % (OS); 53.6 % vs. 36.3 % (CT)). Anti-
depressant users and non-users had approximately equal
proportions that reported a family history of diabetes
(30 % vs. 30.6 % (OS); 31.4 % vs. 31.6 % (CT)) or current
smoking (7.2 % vs. 5.4 % (OS); 9.0 % vs. 7.2 % (CT)).
Mean BMI was similar for those on antidepressants vs.
not (27.91 vs. 26.70 (OS); 29.41 vs. 28.48 (CT)).
OS cohort
Elevated depressive symptoms
An unadjusted model including only baseline values of
antidepressant medication use and presence of elevated
depressive symptoms showed a significant increase in
diabetes risk for those with elevated depressive symp-
toms (HR 1.34; 95 % CI: 1.23-1.45). Approaches 1 and 2
that adjust for other confounders also resulted in a sta-
tistically significant association between the presence of
elevated depressive symptoms and increased risk of dia-
betes – however, this association did not remain statisti-
cally significant in propensity score adjusted models and
MSMs.
Antidepressant medication use
All models showed a consistent, statistically significant
increase in diabetes risk for those exposed to antidepres-
sant medications vs. those who were not (Table 2). Ap-
proach 1 using baseline measures only yielded a HR of
1.19 (95 % CI 1.06 – 1.35). Approach 2 and Approach 3
using time-varying antidepressant medication use, pres-
ence of elevated depressive symptoms and BMI, yielded
almost identical results for antidepressant medication
use [Approach 2: 1.31 (95 % CI 1.18 – 1.46); Approach
3: 1.32 (95 % CI 1.19 – 1.47)]. There were no significant
differences in the HRs estimated for the presence of ele-
vated depressive symptoms between Approaches 2 and
3. The results from MSMs (Approach 4) were almost
identical to Approaches 2 and 3 –the HR (CI) for
antidepressant medication use was 1.35 (95 % CI 1.21 –
1.51). In this application, the MSM approach yielded simi-
lar results to the traditional extended Cox model.
CT cohort
Elevated depressive symptoms
As in the WHI-OS, the unadjusted model showed a sig-
nificant increase in diabetes risk for those with elevated
depressive symptoms. While this association was statisti-
cally significant in Approaches 1 and 2, it did not remain
so in the propensity score adjusted model (Approach 3)
and the MSM (Approach 4).
Antidepressant medication use
As in the WHI OS, all models in the WHI-CT showed a
consistent, statistically significant increase in diabetes
risk for those exposed to antidepressant medications vs.
those who were not.
Table 3 presents an estimate of variation in antidepres-
sant medication use and presence of elevated depressive
symptoms at baseline and year 3, by cohort. In the
WHI-OS, 4.9 % of women were using antidepressant
medication at both time-points, whereas 88.5 % never
used them. 2.2 % of women who were using antidepres-
sant medication at baseline had stopped by year 3, and
4.5 % who were not using antidepressant medication at
baseline had started by year 3. 6.4 % experienced ele-
vated depressive symptoms at both baseline and year 3,
while 76.3 % never did. 8 % of women who experienced
elevated depressive symptoms at baseline did not report
experiencing those symptoms at year 3, and 9.3 % with-
out elevated depressive symptoms at baseline did experi-
ence them by year 3. Similar patterns were observed in
the WHI-CT.
Table 5 (Appendix) presents the HRs and 95 % CIs for
all covariates in the MSMs, in the WHI-OS and CT co-
horts. Table 6 (Appendix) presents the distributions of the
IPTW weights, including the estimated probability of hav-
ing one’s own observed treatment history and censoring
history at follow-up time points. The probability of
remaining uncensored was close to 1 for both cohorts at
each follow-up time point given both the baseline and
time-varying covariates. There was variation in the prob-
ability of having one’s own observed treatment history,
but the mean and median were close to 1 at 36 month
follow-up in the WHI-OS and 12 and 36 month follow-up
in the WHI-CT.
Discussion
Previous research has shown that the prevalence of ele-
vated depressive symptoms and diabetes is high in post-
menopausal women [1, 26]. Ma and colleagues [9] found
an increased risk of type 2 diabetes among women in the
WHI cohorts who reported elevated depressive symptoms
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Table 1 Baseline characteristics of study participants in the Women’s Health Initiative (N = 120,495)
Antidepressant medication use
No Yes Total No Yes Total
N (%) N (%) N (%) N (%) N (%) N (%)
WHI-OS N = 68,169 WHI-CT N = 52,326
Baseline presence of elevated depressive symptomsa
No 54923 (86.7 %) 3440 (71.8 %) 58363 (85.6 %) 42582 (86.7 %) 2238 (70.2 %) 44820 (85.7 %)
Yes 8457 (13.3 %) 1349 (28.2 %) 9806 (14.4 %) 6557 (13.3 %) 949 (29.8 %) 7506 (14.3 %)
Agea
Mean (SD) 63.7 (7.3) 62.1 (7.3) 63.6 (7.3) 62.8 (6.9) 61.77 (6.9) 62.8 (6.9)
Median (IQR) 64.0 (11.0) 62.0 (12.0) 64.0 (11.0) 63.0 (11.0) 61.0 (11.0) 63.0 (11.0)
Ethnicitya
American Indian/Alaskan Native 208 (0.3 %) 19 (0.4 %) 227 (0.3 %) 181 (0.4 %) 8 (0.3 %) 189 (0.4 %)
Asian or Pacific Islander 2009 (3.2 %) 44 (0.9 %) 2053 (3.0 %) 1207 (2.5 %) 22 (0.7 %) 1229 (2.4 %)
Black/African American 4037 (6.4 %) 158 (3.3 %) 4195 (6.2 %) 4266 (8.7 %) 119 (3.7 %) 4385 (8.4 %)
Hispanic/Latino 1845 (2.9 %) 146 (3.1 %) 1991 (2.9 %) 1711 (3.5 %) 85 (2.7 %) 1796 (3.4 %)
White 54614 (86.2 %) 4380 (91.5 %) 58994 (86.5 %) 41243 (83.9 %) 2924 (91.8 %) 44167 (84.4 %)
Other 667 (1.1 %) 42 (0.9 %) 709 (1.0 %) 531 (1.1 %) 29 (0.9 %) 560 (1.1 %)
Education
<= High school 2409 (3.8 %) 189 (4 %) 2598 (3.8 %) 2302 (4.7 %) 144 (4.5 %) 2446 (4.7 %)
High school or GED 9765 (15.5 %) 752 (15.9 %) 10517 (15.5 %) 8991 (18.4 %) 587 (18.5 %) 9578 (18.4 %)
> = High school, but less than 4 years of college 22587 (35.9 %) 1765 (37.2 %) 24352 (36.0 %) 19110 (39.1 %) 1236 (39.0 %) 20346 (39.1 %)
4 or more years of college 28152 (44.7 %) 2036 (42.9 %) 30188 (44.6 %) 18426 (37.7 %) 1199 (37.9 %) 19625 (37.7 %)
BMIa
Mean (SD) 26.7 (5.5) 27.9 (6.0) 26.8 (5.5) 28.5 (5.6) 29.4 (6.0) 28.5 (5.7)
Median (IQR) 25.6 (6.3) 26.7 (7.2) 25.7 (6.4) 27.6 (7.2) 28.4 (8.0) 27.6 (7.2)
Minutes of recreational physical activity per weeka
Mean (SD) 206.9 (186.2) 172.1 (174.8) 204.5 (185.6) 163.2 (169.0) 138.9 (159.2) 161.7 (168.5)
Median (IQR) 165.0 (225.0) 135.0 (212.5) 165.0 (225.0) 125.0 (215.0) 85.0 (195.0) 120.0 (215.0)
Total energy intake (kcal/day)a
Mean (SD) 1533.1 (599.9) 1615.1 (640.4) 1538.8 (603.2) 1716.7 (679.5) 1819.7 (711.9) 1723.0 (682.0)
Median (IQR) 1461.3 (730.1) 1533.2 (765.8) 1465.4 (733.4) 1618.3 (832.5) 1716.3 (870.8) 1623.7 (833.7)
Hormone replacement therapy usea
Never 18423 (29.6 %) 738 (15.7 %) 19161 (28.6 %) 17793 (37.9 %) 662 (21.6 %) 18455 (36.9 %)
Former 12885 (20.7 %) 914 (19.4 %) 13799 (20.6 %) 12122 (25.8 %) 760 (24.8 %) 12882 (25.7 %)
Current 30931 (49.7 %) 3055 (64.9 %) 33986 (50.8 %) 17057 (36.3 %) 1644 (53.6 %) 18701 (37.4 %)
Family history of diabetes
No 41656 (66.0 %) 3114 (65.2 %) 44770 (65.9 %) 31282 (63.9 %) 2022 (63.7 %) 33304 (63.9 %)
Yes 18923 (30.0 %) 1463 (30.6 %) 20386 (30.0 %) 15378 (31.4 %) 1004 (31.6 %) 16382 (31.4 %)
Don’t know 2569 (4.1 %) 198 (4.1 %) 2767 (4.1 %) 2280 (4.7 %) 147 (4.6 %) 2427 (4.7 %)
Smoking statusa
Never smoked 32614 (52.0 %) 2188 (46.2 %) 34802 (51.6 %) 25547 (52.5 %) 1429 (45.2 %) 26976 (52.1 %)
Past smoker 26685 (42.6 %) 2207 (46.6 %) 28892 (42.9 %) 19615 (40.3 %) 1445 (45.7 %) 21060 (40.6 %)
Current smoker 3370 (5.4 %) 339 (7.2 %) 3709 (5.5 %) 3495 (7.2 %) 285 (9.0 %) 3780 (7.3 %)
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(HR 1.13 [95 % CI 1.07–1.20]) and antidepressant use
at baseline (1.18 [95 % CI 1.10–1.28]), based on Cox
models. Multivariable longitudinal analyses confirmed
this relationship with recent antidepressant medica-
tion use, but found only prolonged elevated depres-
sive symptoms to be significantly associated with
increased risk. Our analyses were performed on
120,495 women in the WHI and adjusted for the
same confounders, but utilized Cox models as well as
propensity score adjusted models and MSMs. Our
analyses found a consistent, significant increase in
diabetes risk among those reporting antidepressant
medication use by four different statistical approaches.
In all approaches considered, presence of elevated de-
pressive symptoms was rendered marginally or non-
significant after adjusting for confounders. Our results
are consistent with previous studies examining the
relationship of antidepressant medication use and risk
of type 2 diabetes [3–6, 27, 28].
Of the four different modeling approaches considered in
this paper, MSMs are the gold standard for use in observa-
tional studies in which the presence of time-dependent
confounding (Fig. 2, Appendix) is a possibility. For obser-
vational study settings in the absence of time-dependent
confounding, propensity score adjusted models can be
used to adjust for bias in exposure assignment. Propensity
score adjusted models correct for confounding by indica-
tion – this bias is present in studies in which individuals
who are prescribed or take a medication are inherently
different in their risk profile with respect to outcome
when compared to those who do not take the drug. In the
absence of confounding by indication and time-dependent
confounding, simpler Cox models with or without time-
varying covariates are appropriate.
Table 1 Baseline characteristics of study participants in the Women’s Health Initiative (N = 120,495) (Continued)
Reported diagnosis of diabetes by end of follow-upa
No 60077 (94.8 %) 4468 (93.3 %) 64545 (94.7 %) 45269 (92.1 %) 2886 (90.6 %) 48155 (92.0 %)
Yes 3303 (5.2 %) 321 (6.7 %) 3624 (5.3 %) 3870 (7.9 %) 301 (9.4 %) 4171 (8.0 %)
Years from enrollment to developing diabetesa
Mean (SD) 7.7 (1.5) 7.6 (1.5) 7.7 (1.5) 8.0 (1.7) 7.9 (1.7) 8.0 (1.7)
Median (IQR) 7.9 (2.0) 7.9 (2.0) 7.9 (2.0) 8.0 (1.7) 8.00 (1.9) 8.0 (1.8)
aP – value of <0.002 or lower
Table 2 Hazard ratios for presence of elevated depressive symptoms and antidepressant use with respect to incident diabetes risk
Unadjusted Cox
PH model
Approach 1a Approach 2a Approach 3a Approach 4a
Cox PH Model
(baseline antidepressant
medication use and
baseline presence of
elevated depressive
symptoms)
Cox PH Models
(baseline values
of all predictors)
Cox Models (time varying
antidepressant medication
use, presence of elevated
depressive symptoms, and
BMI; baseline values for other
covariates)
Cox Models (time varying
antidepressant medication
use, presence of elevated
depressive symptoms, and
BMI; adjusted for propensity
score and baseline values for
other covariates)
Marginal Structural Models
(time varying antidepressant
medication use, presence
of elevated depressive
symptoms, and BMI; baseline
values for other covariates)
Predictor HR (95 % CI) HR (95 % CI) HR (95 % CI) HR (95 % CI) HR (95 % CI)
Observational Cohort (OS) (N = 68,169)
Antidepressant
medication use
up to year 3
1.26 1.19 1.31 1.32 1.35
(1.12–1.41) (1.06–1.35) (1.18–1.46) (1.19–1.47) (1.21–1.51)
Presence of
elevated
depressive
symptoms
1.34 1.11 1.12 1.09 1.10
(1.23–1.45) (1.02–1.21) (1.03–1.23) (1.00–1.19) (1.00–1.20)
Clinical Trial (CT) (N = 52,326)
Antidepressant
medication use
up to year 3
1.17 1.14 1.26 1.25 1.27
(1.04–1.31) (1.01–1.30) (1.12–1.41) (1.12–1.40) (1.13–1.43)
Presence of
elevated
depressive
symptoms
1.31 1.13 1.12 1.09 1.10
(1.21–1.42) (1.04–1.23) (1.03–1.22) (0.996–1.18) (1.00–1.20)
aModels adjusted for baseline values of age, ethnicity, education, minutes of recreational physical activity per week, total energy intake, hormone therapy use,
family history of diabetes and smoking status
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Table 3 Estimate of variation in presence of depressive symptoms and antidepressant medication use over time
WHI-OS N = 68,169
Antidepressant use at baseline No antidepressant use at baseline
N (%) N (%)
Antidepressant use at year 3 3321 (4.9 %) 3083 (4.5 %)
No antidepressant use at year 3 1468 (2.2 %) 60297 (88.5 %)
Presence of elevated symptoms at baseline No presence of elevated symptoms at baseline
N (%) N (%)
Presence of elevated symptoms at year 3 4348 (6.4 %) 6333 (9.3 %)
No presence of elevated symptoms at year 3 5458 (8.0 %) 52030 (76.3 %)
Baseline Year 3
Mean (SD) Mean (SD)
BMI 26.80 (5.5) 27.09 (5.6)
WHI-CT N = 52,326
Antidepressant use at baseline No antidepressant use at baseline
N (%) N (%)
Antidepressant use at year 3 2031 (3.9 %) 1979 (3.8 %)
No antidepressant use at year 3 1156 (2.2 %) 47160 (90.1 %)
Baseline Year 3
Mean (SD) Mean (SD)
BMI 28.54 (5.7) 28.78 (5.9)
Fig. 2 Illustration of time-dependent confounding by BMI in the association of antidepressant medication use and time to development of
diabetes. Illustrates the hypothesis that there is time-varying confounding by BMI with regard to the association between diabetes risk and the
presence of elevated depressive symptoms/antidepressant use. Let A denote the exposure or presence of elevated depressive symptoms/
antidepressant use, L denotes measured covariates such as BMI or race, U denotes unmeasured covariates and Y denotes the outcome
(diabetes). The causal graph illustrates that the probabilities of elevated depressive symptoms/antidepressant medication use (A) depends
on BMI (L), but not U. There is confounding by measured covariates, but no confounding by unmeasured covariates. The probabilities of
elevated depressive symptoms/antidepressant medication use at baseline (A(0)) is influenced by baseline BMI (L(0)). In our example, confounding is
time dependent because exposure at time 1 (A(1)) is affected by previous exposure (A(0)) and BMI at time 1 (L(1))
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We did not observe differences in hazard ratio esti-
mates between the four modeling approaches that were
considered. One explanation for the concordance of esti-
mates from these different approaches suggests that
time-dependent confounding by BMI was not a substan-
tial factor in these data – thus, BMI measured over the
course of observation may not be strongly affected by
exposure (i.e., as an intermediate) and/or did not exert a
strong influence on our exposure and outcome of inter-
est (i.e., as a confounder). However, other potential ex-
planations for this observed concordance of results
include limited longitudinal measurements of the key
exposure variables, measurement error of the con-
founder and/or incorrect model specification of the dose
response relationship with respect to the effects of the
confounder on both exposure and outcome. However,
this study was not designed to pinpoint the specific fac-
tor that caused the concordance of estimates from the
various models.
A limitation of this work is that we had limited longi-
tudinal follow up. The WHI-OS had two repeated mea-
sures, at baseline and at year 3. The WHI-CT had more
repeated measures available, but we were only able to
utilize three time points (baseline, year 1, year 3) due to
high levels of missing data at later time points. In
addition, in the WHI-CT, because presence of elevated
depressive symptoms was measured on only a small per-
centage of participants after year 1, our models could
not incorporate this factor as a time varying exposure.
Due to limitations of the available data, the analysis did
not account for antidepressant dose and adherence.
While a bidirectional association between depression
and diabetes risk is biologically plausible, our study was
not designed to tease out the direction of association.
Lastly, due to cost considerations, diabetes status was
ascertained through self-reported questionnaires – this
could result in modest levels of outcome misclassifica-
tion. Statistical models that account for the error-prone
self-reported outcomes would be useful in this context.
Conclusions
Our analyses provide further evidence that a significant
increase in diabetes risk is observed for those on anti-
depressant medications in the WHI. In addition, our re-
sults comparing modeling approaches demonstrates that
in some settings, results from more complex methods
such as MSMs may not differ substantially from trad-
itional methods of analysis – however, we recommend
that these methods be explored to establish the validity
of initial findings.
Appendix
SAS Code to Fit the Marginal Structural Cox Proportional
Hazards Model
Here we provide details on how to set up the data,
along with SAS code to perform the analyses in Ap-
proach 4 using Marginal Structural Models for a time to
event outcome. The first part of the analysis uses the
proc logistic procedure to calculate the probability of
not being on antidepressants (Models 1 and 2). Data in
the file ‘iptw’ contains 1 record per subject for each time
point included in the analysis. For example, in the WHI-
OS dataset, we have measurements at baseline and year
3. Each subject has two records, one for baseline and
one for year 3. Next we use the proc logistic procedure
to calculate the probability of not being censored
(Models 3 and 4). In the data file ‘iptw2’ the data has
been expanded so that a subject has 1 record per month
until her time to diabetes or time to censoring. The
dataset ‘main’ merges Models 1-4 together to calculate
the IPTW weights. This again is an expanded dataset so
a subject has 1 record per month until her time to dia-
betes or time to censoring. The dataset ‘main_w’ con-
tains the inverse probability of treatment weights and is
the dataset used to run the marginal structural model
analysis. Last, we use the proc genmod procedure to fit
the final pooled logistic regression model to obtain the
estimates of our association of interest.
Antidep is a dichotomous 0/1 indicator of the partici-
pant being on or off antidepressants. Model 1 includes
that dichotomous indicator as the outcome, a time-
dependent intercept and baseline values of the following
covariates as predictors: presence of elevated depressive
symptoms (base_depression), BMI (base_bmi),
Age (age), Ethnicity (ethnic), Education (educ4),
Minutes of physical activity per week (tminwk),
Total energy intake (base_energy_cat), Family
history of diabetes (diabrel), Hormone therapy
use (hormstat) and smoking status (smoking).
Model 2 mirrors Model 1 with the addition of the
most recent time-dependent values of the following
covariates: presence of elevated depressive symptoms
(depression), and BMI (bmi).
The outcome variable in Models 3 and 4 is a dichot-
omous indicator of whether or not the participant has
been censored up to that time point. Model 3 includes
as regressors the baseline values for the following co-
variates: the dichotomous indicator of antidepressant
medication use (antidep), presence of elevated
depressive symptoms (base_depression), BMI
(base_bmi), Age (age), Ethnicity (ethnic),
Education (educ4),Minutes of physical activity per week
(tminwk), Total energy intake (base_energy_cat),
Family history of diabetes (diabrel), Hormone therapy
use (hormstat) and smoking status (smoking). All
available person months are included. Model 4 mirrors
Model 3 with the inclusion of the most recent time-
dependent value of the following covariates: antidepressant
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Table 4 Baseline characteristics of study participants, by presence of elevated depressive symptoms
Presence of elevated depressive symptoms
No Yes Total No Yes Total
N (%) N (%) N (%) N (%) N (%) N (%)
WHI-OS N = 68,169 WHI-CT N = 52,326
Antidepression medication usea
No 54923 (94.1 %) 8457 (86.2 %) 63380 (93.0 %) 42582 (95.0 %) 6557 (87.4 %) 49139 (93.9 %)
Yes 3440 (5.9 %) 1349 (13.8 %) 4789 (7.0 %) 2238 (5.0 %) 949 (12.6 %) 3187 (6.1 %)
Agea
Mean(SD) 63.7 (7.2) 62.9 (7.5) 63.6 (7.3) 62.9 (6.9) 61.8 (7.1) 62.8 (6.9)
Median(IQR) 64.0 (11.0) 63.0 (12.0) 64.0 (11.0) 63.0 (11.0) 61.0 (11.0) 63.0 (11.0)
Ethnicitya
American Indian/Alaskan Native 172 (0.3 %) 55 (0.6 %) 227 (0.3 %) 151 (0.3 %) 38 (0.5 %) 189 (0.4 %)
Asian or Pacific Islander 1839 (3.2 %) 214 (2.2 %) 2053 (3.0 %) 1124 (2.5 %) 105 (1.4 %) 1229 (2.4 %)
Black/African American 3490 (6.0 %) 705 (7.2 %) 4195 (6.2 %) 3607 (8.1 %) 778 (10.4 %) 4385 (8.4 %)
Hispanic/Latino 1478 (2.5 %) 513 (5.2 %) 1991 (2.9 %) 1313 (2.9 %) 483 (6.4 %) 1796 (3.4 %)
White 50798 (87 %) 8196 (83.6 %) 58994 (86.5 %) 38158 (85.1 %) 6009 (80.1 %) 44167 (84.4 %)
Other 586 (1.0 %) 123 (1.3 %) 709 (1.0 %) 467 (1.0 %) 93 (1.2 %) 560 (1.1 %)
Educationa
<= High school 1957 (3.4 %) 641 (6.6 %) 2598 (3.8 %) 1837 (4.1 %) 609 (8.2 %) 2446 (4.7 %)
High school or GED 8784 (15.2 %) 1733 (17.8 %) 10517 (15.5 %) 8074 (18.1 %) 1504 (20.2 %) 9578 (18.4 %)
> = High school, but less than 4 years of college 20643 (35.6 %) 3709 (38.2 %) 24352 (36.0 %) 17315 (38.9 %) 3031 (40.7 %) 20346 (39.1 %)
4 or more years of college 26557 (45.8 %) 3631 (37.4 %) 30188 (44.6 %) 17330 (38.9 %) 2295 (30.9 %) 19625 (37.7 %)
BMIa
Mean(SD) 26.7 (5.4) 27.6 (6.0) 26.8 (5.5) 28.4 (5.6) 29.3 (6.0) 28.5 (5.7)
Median(IQR) 25.6 (6.3) 26.5 (7.1) 25.7 (6.4) 27.5 (7.1) 28.4 (7.7) 27.6 (7.2)
Minutes of recreational physical activity per weeka
Mean(SD) 210.1 (186.6) 170.8 (175.7) 204.5 (185.6) 165.4 (168.7) 139.7 (165.5) 161.7 (168.5)
Median(IQR) 170.0 (225.0) 127.5 (220.0) 165.0 (225.0) 125.0 (220.0) 85.0 (200.0) 120.0 (215.0)
Total energy intake (kcal/day)a
Mean(SD) 1529.7 (588.9) 1593.2 (679.5) 1538.8 (603.2) 1710.7 (666.7) 1796.8 (762.7) 1723.0 (682.0)
Median(IQR) 1461.9 (719.7) 1493.9 (817.1) 1465.4 (733.4) 1618.0 (815.0) 1671.6 (951.6) 1623.7 (833.7)
HRT use evera
Never 16498 (28.8 %) 2663 (27.7 %) 19161 (28.6 %) 15945 (37.2 %) 2510 (34.9 %) 18455 (36.9 %)
Former 11590 (20.2 %) 2209 (22.9 %) 13799 (20.6 %) 10805 (25.2 %) 2077 (28.9 %) 12882 (25.7 %)
Current 29228 (51.0 %) 4758 (49.4 %) 33986 (50.8 %) 16099 (37.6 %) 2602 (36.2 %) 18701 (37.4 %)
Relative had adult diabetesa
No 38718 (66.6 %) 6052 (62.0 %) 44770 (65.9 %) 28802 (64.5 %) 4502 (60.3 %) 33304 (63.9 %)
Yes 17225 (29.6 %) 3161 (32.4 %) 20386 (30.0 %) 13867 (31.1 %) 2515 (33.7 %) 16382 (31.4 %)
Smoking statusa
Never Smoked 29984 (52.0 %) 4818 (49.7 %) 34802 (51.6 %) 23382 (52.7 %) 3594 (48.4 %) 26976 (52.1 %)
Past Smoker 24751 (42.9 %) 4141 (42.7 %) 28892 (42.9 %) 18012 (40.6 %) 3048 (41.1 %) 21060 (40.6 %)
Current Smoker 2971 (5.1 %) 738 (7.6 %) 3709 (5.5 %) 3004 (6.8 %) 776 (10.5 %) 3780 (7.3 %)
Reported diagnosis of diabetes by end of follow-upa
No 55407 (94.9%) 9138 (93.2%) 64545 (94.7%) 41399 (92.4%) 6756 (90.0%) 48155 (92.0%)
Yes 2956 (5.1%) 668 (6.8%) 3624 (5.3%) 3421 (7.6%) 750 (10.0%) 4171 (8.0%)
Frisard et al. BMC Endocrine Disorders  (2015) 15:56 Page 10 of 15
medication use (antidepressant_tv), presence of el-
evated depressive symptoms (depression) and BMI
(bmi). Models 3 and 4 also include variables for ‘month’
and ‘month2’ to relax the linearity assumption.
We merge Models 1-4 together and in the following
data step use the predicted values from those models to
compute our IPTW estimates, denoted by stabw and
nstabw for the stabilized and non-stabilized weights,
respectively.
In our last step, we use the proc genmod procedure
to fit the weighted pooled logistic model to obtain es-
timates of our association of interest from our Mar-
ginal Structural Cox PH Model. The outcome here is
diabetes, which is a dichotomous indicator of whether
or not the participant developed diabetes during that
month. The patient ID variable and the independent
working correlation matrix (subject = id/type = ind)
must be specified. We weighted the model used the
stabilized weights by using the ‘scwgt stabw’ statement
in the procedure. The ‘estimate’ statement asks the
procedure to report the odds ratio for our main asso-
ciations of interest, in addition to the coefficients in
the model.
/*calculate probability of not being on
antidepressants*/
/* Model 1*/
proc sort data=iptw;
by id month;
run;
proc logistic data=iptw;
class base_depression ethnic educ4
base_energy_cat hormstat smoking diabrel;
where month=36;
model antidep=base_depression base_bmi
age ethnic educ4 tminwk base_energy_cat
diabrel hormstat smoking month;
output out=model1 p=pandep_0_temp;
run;
/* Model 2*/
proc logistic data=iptw;
where month=36;
class base_depression depression ethnic
educ4 base_energy_cat energy_cat hormstat
smoking diabrel;
model antidep=base_depression depression
base_bmi bmi age ethnic educ4 tminwk
base_energy_cat diabrel hormstat smoking
month;
output out=model2 p=pandep_w_temp;
run;
/*calculate probability of not being
censored*/
/* Model 3*/
proc logistic data=iptw2;
class antidep depression ethnic educ4
base_energy_cat hormstat smoking diabrel;
model censor_tv=antidep depression bmi
age ethnic educ4 tminwk base_energy_cat
diabrel hormstat smoking month month_sq;
output out=model3 p=punc_0;
run;
/* Model 4*/
proc logistic data=iptw2;
class antidep antidepressant_tv depression
depression_tv ethnic educ4 base_energy_cat
hormstat smoking diabrel;
model censor_tv=antidep antidepressant_tv
depression bmi age ethnic educ4 tminwk
base_energy_cat diabrel hormstat smoking
depression_tv bmi_tv month month_sq;
output out=model4 p=punc_w;
run;
/*merge data*/
data main;
merge temp1 temp2 model3(in=a)
model4(in=b);
by id month; if a=1 and b=1;
if first.id then do;
pandep_0 = 1;
pandep_w = 1;
end;
if month=36 then do;
pandep_0=pandep_0_temp;
pandep_w=pandep_w_temp;
end;
retain pandep_0 pandep_w;
run;
/* Calculate the weights*/
data main_w;
set main;
by id month;
/*reset variables for a new patient*/
Table 4 Baseline characteristics of study participants, by presence of elevated depressive symptoms (Continued)
Years from enrollment to development of diabetesa
Mean(SD) 7.7 (1.5) 7.6 (1.6) 7.7 (1.5) 8.0 (1.7) 7.9 (1.8) 8.0 (1.7)
Median(IQR) 7.9 (2.0) 7.9 (2.0) 7.9 (2.0) 8.0 (1.7) 8.0 (1.9) 8.0 (1.8)
Don’t Know 2212 (3.8 %) 555 (5.7 %) 2767 (4.1 %) 1975 (4.4 %) 452 (6.1 %) 2427 (4.7 %)
aP-value <0.007 or lower
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Table 5 Inverse probability of treatment-weighted estimates of the marginal structural model
Parameter Estimate SE 95 % Confidence limits HR (95 % CI) P-Value
WHI-OS
Antidepressant medication use <.0001
Yes 0.30 0.06 0.19 0.41 1.35 (1.21-1.51)
No 0.00 0.00 0.00 0.00 1 .
Presence of elevated depressive symptoms 0.04
Yes 0.09 0.05 0.00 0.18 1.09 (1.00-1.20)
No 0.00 0.00 0.00 0.00 1 .
Ethnicity
American Indian/Alaskan Native 0.72 0.20 0.32 1.12 2.05 (1.38-3.06) 0.0004
Asian or Pacific Islander 0.78 0.09 0.61 0.95 2.18 (1.84-2.59) <.0001
Black/African American 0.56 0.06 0.46 0.67 1.75 (1.58-1.95) <.0001
Hispanic/Latino 0.52 0.09 0.35 0.69 1.68 (1.42-1.99) <.0001
White 0.00 0.00 0.00 0.00 1 .
Other 0.35 0.15 0.05 0.65 1.42 (1.05-1.92) 0.02
Education level
<= high school 0.37 0.08 0.22 0.52 1.45 (1.25-1.68) <.0001
High school or GED 0.29 0.05 0.19 0.39 1.34 (1.21-1.48) <.0001
> = High school, but less than 4 years of college 0.22 0.04 0.14 0.30 1.25 (1.15-1.35) <.0001
4 or more years of college 0.00 0.00 0.00 0.00 1 .
Minutes or recreational physical activity per week -0.0006 0.0001 -0.0008 -0.0004 0.9994 (0.9992-0.9996) <.0001
Family history of diabetes
No -0.78 0.04 -0.85 -0.71 0.46 (0.43-0.49) <.0001
Yes 0.00 0.00 0.00 0.00 1 .
Don’t know -0.41 0.08 -0.57 -0.24 0.66 (0.57-0.79) <.0001
Hormone therapy use
Never 0.00 0.00 0.00 0.00 1 .
Former 0.01 0.05 -0.09 0.10 1.01 (0.91-1.11) 0.89
Current -0.12 0.04 -0.20 -0.04 0.89 (0.82-0.96) 0.004
Smoking status
Never smoked 0.00 0.00 0.00 0.00 1 .
Past smoker 0.05 0.04 -0.03 0.12 1.05 (0.97-1.13) 0.21
Current smoker 0.17 0.07 0.03 0.31 1.19 (1.03-1.36) 0.02
BMI 0.08 0.00 0.08 0.08 1.08 (1.08-1.09) <.0001
Age 0.02 0.00 0.01 0.02 1.02 (1.01-1.02) <.0001
Baseline total energy intake
4.87- 1100.54 -0.21 0.05 -0.30 -0.11 0.81 (0.74-0.90) <.0001
1100.55- 1437.42 -0.24 0.05 -0.33 -0.14 0.79 (0.72-0.87) <.0001
1437.44- 1828.01 -0.18 0.05 -0.27 -0.08 0.84 (0.76-0.92) 0.00
> = 1828.02 0.00 0.00 0.00 0.00 1 .
WHI-CT
Antidepressant medication use <.0001
Yes 0.24 0.06 0.13 0.36 1.27 (1.14-1.43)
No 0.00 0.00 0.00 0.00 1 .
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Table 5 Inverse probability of treatment-weighted estimates of the marginal structural model (Continued)
Presence of elevated depressive symptoms 0.04
Yes 0.09 0.05 0.00 0.18 1.09 (1.00-1.20)
No 0.00 0.00 0.00 0.00 1 .
Ethnicity
American Indian/Alaskan Native 0.09 0.26 -0.41 0.60 1.09 (0.66-1.82) 0.71
Asian or Pacific Islander 0.73 0.10 0.54 0.91 2.08 (1.72-2.48) <.0001
Black/African American 0.41 0.05 0.32 0.51 1.51 (1.38-1.67) <.0001
Hispanic/Latino 0.50 0.08 0.35 0.65 1.65 (1.42-1.92) <.0001
White 0.00 0.00 0.00 0.00 1 .
Other 0.38 0.14 0.10 0.65 1.46 (1.11-1.92) 0.007
Education
<= high school 0.32 0.07 0.18 0.46 1.38 (1.20-1.58) <.0001
High school or GED 0.20 0.05 0.10 0.29 1.22 (1.11-1.34) <.0001
> = High school, but less than 4 years of college 0.22 0.04 0.14 0.30 1.25 (1.15-1.35) <.0001
4 or more years of college 0.00 0.00 0.00 0.00 1 .
Minutes or recreational physical activity per week -0.001 0.000 -0.001 0.000 0.999 (0.999-1.000) <.0001
Family history of diabetes
Yes 0.00 0.00 0.00 0.00 1 .
No -0.68 0.03 -0.75 -0.61 0.51 (0.47-0.54) <.0001
Don’t know -0.32 0.07 -0.47 -0.18 0.73 (0.63-0.84) <.0001
Hormone therapy use
Never 0.00 0.00 0.00 0.00 1 .
Former -0.002 0.04 -0.08 0.08 0.998 (0.92-1.08) 0.97
Current -0.17 0.05 -0.26 -0.09 0.84 (0.77-0.91) 0.0001
Smoking status
Never smoked 0.00 0.00 0.00 0.00 1 .
Past smoker -0.01 0.04 -0.08 0.06 0.99 (0.92-1.06) 0.78
Current smoker 0.19 0.06 0.07 0.32 1.21 (1.07-1.38) 0.002
BMI 0.07 0.00 0.07 0.08 1.07 (1.07-1.08) <.0001
Age 0.02 0.00 0.01 0.02 1.02 (1.01-1.02) <.0001
Baseline total energy intake
4.87- 1100.54 -0.04 0.05 -0.13 0.06 0.96 (0.88-1.06) 0.46
1100.55- 1437.42 -0.04 0.05 -0.13 0.05 0.96 (0.88-1.05) 0.43
1437.44- 1828.01 -0.06 0.04 -0.15 0.03 0.94 (0.86-1.03) 0.17
1828.02- 23020.93 0 0 0 0 1 .
Participated in hormone therapy trial 0.07
Yes 0.09 0.05 -0.01 0.20 1.09 (0.99-1.22)
No 0 0 0 0 1 .
Participated in dietary modification trial 0.07
Yes 0.10 0.05 -0.01 0.20 1.11 (0.99-1.22)
No 0 0 0 0 1 .
Participated in calcium/ vitamin D supplementation 0.44
Yes -0.03 0.03 -0.09 0.04 0.97 (0.91-1.04)
No 0 0 0 0 1 .
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if first.id then do;
k2_0=1; k2_w=1;
end;
retain k2_0 k2_w;
/*inverse probability of censoring
weights*/
else do;
k2_0=k2_0*punc_0;
k2_w=k2_w*punc_w;
end;
/* Inverse probability of treatment
weights */
if antidepressant_tv=0 and month>=36
then k1_0=pandep_0;
if antidepressant_tv=0 and month>=36
then k1_w=pandep_w;
if antidepressant_tv=1 and month>=36
then k1_0=(1-pandep_0);
if antidepressant_tv=1 and month>=36
then k1_w=(1-pandep_w);
if month<36 then k1_0=1;
if month<36 then k1_w=1;
/* Stabilized and non stabilized weights
*/
stabw=(k1_0*k2_0)/(k1_w*k2_w);
nstabw=1/(k1_w*k2_w);
run;
/* Pooled logistic regression model to
run the MSM analysis */
proc genmod data=main_w descending;
class id ethnic educ4 hormstat smoking
base_energy_cat diabrel;
model diabetes_tv=antidepressant_tv eth-
nic educ4 tminwk diabrel hormstat smoking
depression_tv bmi_tv age base_energy_cat
month month_sq/ link=logit dist=bin;
scwgt stabw;
repeated subject=id/ type=ind;
estimate "log O.R. antidepressant"
antidepressant_tv 1 / exp;
estimate "log O.R. depressive symptoms"
depression_tv 1 / exp;
run;
Abbreviations
WHI-CT: Women’s health initiative clinical trials cohort; WHI-OS: Women’s
health initiative observational cohort; WHI: Women’s Health Initiative;
BMI: Body mass index; IPTW: Inverse probability of treatment weights;
CES-D: Center for Epidemiological Studies Depression Scale; PH: Cox
Table 6 Estimated probability of having one’s own observed treatment history and censoring history at follow-up
N Mean SD Median Quartile range Minimum Maximum
WHI-OS
36 months
Probability of having observed antidepressant medication history
Given baseline covariates 64048 0.91 0.05 0.91 0.06 0.49 0.99
Given time-varying covariates 64048 0.91 0.06 0.92 0.06 0.36 0.99
Probability of being uncensored
Given baseline covariates 64099 0.99983 0.0000271 0.9998275 0.0000380 0.99963 0.99988
Given time-varying covariates 64099 0.99983 0.0000273 0.9998275 0.0000381 0.99964 0.99988
WHI-CT
12 months
Probability of having observed antidepressant medication history
Given baseline covariates 46084 0.93 0.05 0.94 0.05 0.52 0.995
Given time-varying covariates 46084 0.93 0.05 0.94 0.05 0.30 0.996
Probability of being uncensored
Given baseline covariates 46084 0.9999997 6.7564221E-8 0.9999997 9.1169629E-8 0.9999992 0.9999998
Given time-varying covariates 46084 0.9999997 6.7917506E-8 0.9999997 9.1473164E-8 0.9999992 0.9999998
36 months
Probability of having observed antidepressant medication history
Given baseline covariates 45235 0.86 0.09 0.88 0.10 0.24 0.99
Given time-varying covariates 45235 0.86 0.09 0.88 0.10 0.20 0.99
Probability of being uncensored
Given baseline covariates 45235 0.999971 6.6963806E-6 0.999971 9.041897E-6 0.99992 0.99998
Given time-varying covariates 45235 0.999971 6.7459345E-6 0.999971 9.0819261E-6 0.99992 0.99998
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Proportional Hazards; CI: Confidence interval; HR: Hazard ratio;
MSMs: Marginal structural models.
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